Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott paclitaxel

Executive Summary

NaPro will supply bulk drug and license its paclitaxel related patents, including 12 issued and nine pending U.S. patents to Abbott under a development agreement. Abbott will be responsible for formulation, regulatory submissions, and marketing of the paclitaxel product. NaPro will participate in the conduct of clinical trials, which have begun recruiting, and received milestone payments and royalties. The agreement covers U.S. and Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS034577

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel